1
|
Callejón-Leblic B, Sánchez Espirilla S, Gotera-Rivera C, Santana R, Díaz-Olivares I, Marín JM, Macario CC, Cosio BG, Fuster A, García IS, de-Torres JP, Feu Collado N, Cabrera Lopez C, Amado Diago C, Romero Plaza A, Fraysse LAP, Márquez Martín E, Marín Royo M, Balcells Vilarnau E, Llunell Casanovas A, Martínez González C, Galdíz Iturri JB, Lacárcel Bautista C, Gómez-Ariza JL, Pereira-Vega A, Seijo L, López-Campos JL, Peces-Barba G, García-Barrera T. Metallomic Signatures of Lung Cancer and Chronic Obstructive Pulmonary Disease. Int J Mol Sci 2023; 24:14250. [PMID: 37762552 PMCID: PMC10532173 DOI: 10.3390/ijms241814250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 09/07/2023] [Accepted: 09/08/2023] [Indexed: 09/29/2023] Open
Abstract
Lung cancer (LC) is the leading cause of cancer deaths, and chronic obstructive pulmonary disease (COPD) can increase LC risk. Metallomics may provide insights into both of these tobacco-related diseases and their shared etiology. We conducted an observational study of 191 human serum samples, including those of healthy controls, LC patients, COPD patients, and patients with both COPD and LC. We found 18 elements (V, Al, As, Mn, Co, Cu, Zn, Cd, Se, W, Mo, Sb, Pb, Tl, Cr, Mg, Ni, and U) in these samples. In addition, we evaluated the elemental profiles of COPD cases of varying severity. The ratios and associations between the elements were also studied as possible signatures of the diseases. COPD severity and LC have a significant impact on the elemental composition of human serum. The severity of COPD was found to reduce the serum concentrations of As, Cd, and Tl and increased the serum concentrations of Mn and Sb compared with healthy control samples, while LC was found to increase Al, As, Mn, and Pb concentrations. This study provides new insights into the effects of LC and COPD on the human serum elemental profile that will pave the way for the potential use of elements as biomarkers for diagnosis and prognosis. It also sheds light on the potential link between the two diseases, i.e., the evolution of COPD to LC.
Collapse
Affiliation(s)
- Belén Callejón-Leblic
- Department of Chemistry, Research Center for Natural Resources, Health and the Environment (RENSMA), Faculty of Experimental Sciences, University of Huelva, Campus El Carmen, Fuerzas Armadas Ave., 21007 Huelva, Spain; (B.C.-L.); (S.S.E.); (J.L.G.-A.)
| | - Saida Sánchez Espirilla
- Department of Chemistry, Research Center for Natural Resources, Health and the Environment (RENSMA), Faculty of Experimental Sciences, University of Huelva, Campus El Carmen, Fuerzas Armadas Ave., 21007 Huelva, Spain; (B.C.-L.); (S.S.E.); (J.L.G.-A.)
- Department of Chemistry, Faculty of Sciences, National University of San Antonio Abad of Cusco, Av. de La Cultura, Cusco 773, Peru
| | - Carolina Gotera-Rivera
- IIS-Jiménez Díaz Foundation, ISCIII-CIBERES, Reyes Católicos Ave., 28040 Madrid, Spain; (C.G.-R.); (R.S.)
| | - Rafael Santana
- IIS-Jiménez Díaz Foundation, ISCIII-CIBERES, Reyes Católicos Ave., 28040 Madrid, Spain; (C.G.-R.); (R.S.)
| | - Isabel Díaz-Olivares
- Beturia Andalusian Foundation for Health Research (FABIS), Ronda Norte, s/n, 21005 Huelva, Spain;
| | - José M. Marín
- Miguel Servet Hospital-IIS Aragon, ISCIII-CIBERES, Paseo de Isabel la Católica, 1-3, 50009 Zaragoza, Spain;
| | - Ciro Casanova Macario
- Pulmonary Department—Research Unit, Hospital Universitario Nuestra Señora de Candelaria, CIBERES, ISCIII, Universidad de La Laguna, Padre Herrera, s/n, 38200 Santa Cruz de Tenerife, Spain;
| | - Borja García Cosio
- Son Espases Hospital, IdISBa, ISCIII-CIBERES, Valldemossa Road, 79, 07120 Palma De Mallorca, Spain;
| | - Antonia Fuster
- Son Llàtzer Hospital, C. de Manacor, 07198 Palma, Spain;
| | - Ingrid Solanes García
- Santa Creu i Sant Pau Hospital, Carrer de St. Antoni Maria Claret, 167, 08025 Barcelona, Spain;
| | - Juan P. de-Torres
- University Clinic of Navarra, Pío XII Ave., 36, 31008 Pamplona, Spain;
| | - Nuria Feu Collado
- Reina Sofía Hospital, Maimonides Institute for Biomedical Research of Córdoba, Menéndez Pidal Ave., s/n, 14004 Córdoba, Spain;
| | - Carlos Cabrera Lopez
- University Hospital of Gran Canaria Dr. Negrín, Respiratory Service, C. Pl. Barranco de la Ballena, s/n, 35010 Las Palmas de Gran Canarias, Spain;
| | | | | | | | - Eduardo Márquez Martín
- Virgen del Rocío Hospital, Institute of Biomedicine of Seville (IBiS), ISCIII-CIBERES, Manuel Siurot Ave., s/n, 41013 Seville, Spain;
| | | | - Eva Balcells Vilarnau
- Hospital del Mar, ISCIII-CIBERES, Paseo Marítimo de la Barceloneta, 25, 29, 08003 Barcelona, Spain;
| | | | | | | | | | - José Luis Gómez-Ariza
- Department of Chemistry, Research Center for Natural Resources, Health and the Environment (RENSMA), Faculty of Experimental Sciences, University of Huelva, Campus El Carmen, Fuerzas Armadas Ave., 21007 Huelva, Spain; (B.C.-L.); (S.S.E.); (J.L.G.-A.)
| | - Antonio Pereira-Vega
- Pneumology Area of the Juan Ramón Jiménez Hospital, Ronda Norte, s/n, 21005 Huelva, Spain; (L.A.P.F.); (A.P.-V.)
| | - Luis Seijo
- University Clinic of Navarra, ISCIII-CIBERES, Monforte de Lemos Ave., 28029 Madrid, Spain;
| | - José Luis López-Campos
- Medical-Surgical Unit for Respiratory Diseases, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, Manuel Siurot Ave., s/n, 41013 Sevilla, Spain;
- Center for Biomedical Research in Respiratory Diseases Network (CIBERES), Carlos III Health Institute, Av. de Monforte de Lemos, 3–5, 28029 Madrid, Spain
| | - Germán Peces-Barba
- IIS-Jiménez Díaz Foundation, ISCIII-CIBERES, Reyes Católicos Ave., 28040 Madrid, Spain; (C.G.-R.); (R.S.)
| | - Tamara García-Barrera
- Department of Chemistry, Research Center for Natural Resources, Health and the Environment (RENSMA), Faculty of Experimental Sciences, University of Huelva, Campus El Carmen, Fuerzas Armadas Ave., 21007 Huelva, Spain; (B.C.-L.); (S.S.E.); (J.L.G.-A.)
| |
Collapse
|
3
|
Cárdenas Quesada N, Ortega Granados AL, Márquez Lobo B, Vivo Molina MC, Rosa Garrido C, Piedra Fernández I, Sevilla López S, Cerro AB, Lacárcel Bautista C, Pérez Chica G, Nieto Serrano J, García Verdejo FJ, Luque Caro N, Fernández Garay D, Moreno Jimenez MA, Plata Fernández Y, Núñez Torres MI, Sánchez Rovira P. Histological features and survival in NSCLC patients treated with surgery with curative intention. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e20080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20080 Background: New classification of adenocarcinomas and better typing of histological characteristics of lung tumors leads us to wonder if these histological data could have a prognostic repercussion in the NSCLC who were into curative intent surgery Methods: We followed 95 patients with stage I-III NSCLC underwent surgery in a 4 year period (2010-2013), until August 2016. Most patients were male (82%), smokers (90%, 44% exsmokers and 56% active , median age at diagnosis was 64 years, 47% had a previous COPD, and 52% were diagnosed of NSCLC without any symptom of lung cancer. 79% patients had lobectomy or sleeve resection, and 21% pneumonectomy. 47% patients had adjuvant chemotherapy (CT) Results: We found no significant differences in age of diagnosis between men (64.95 y) and women (58.65 y) (p = 0.066) nor in survival time. Median disease-free survival (DFS) is 15 months and overall survival (OS) is 49 months. If we analyze DFS from surgery to the first relapse, most happen at first 2 years (80%). By stage, OS at 5 years is 73% in stage IA, 58% stage IB, 46% stage IIA, 36% stage IIB, 24% for stage IIIA and 9% in IIIB. We had 49% adenocarcinomas (most frequent, 53%, acinar subtype), and 51% squamous, and we found no significant difference between histologies, nor between subtypes. But there was a significant difference between DFS, favorable for mild lymphoid response (20 months) with respect to moderate or intense response (11 months) Conclusions: We found that we are underusing adjuvant CT. In our group there is no difference in survival for tumor size, linfovascular invasion, histological grade or histology, but we found a better DFS for mild lymphoid response vs moderate-intense pattern. This finding may be related to the antitumor activity of the immune system, and we want to validate it prospectively, and its relationship with subsequent immune therapy response.
Collapse
|